Horizon Discovery to Expand and Establish New UK Headquarters at IQ Cambridge

23 Nov 2009

Horizon Discovery (Horizon), the UK Personalized Medicine company recently announced as the Best Technology Start-Up and Best Technology Company at the inaugural UK government sponsored iawards, today announced that it is to expand its operations to include a purpose-fitted office and wet-lab facility at IQ Cambridge which will house up to 20 new staff.

The move will enable the company to service over $12,000,000 of commercial orders received in 2009. The facility is complimented by the company’s state-of-art molecular biology facility in Torino, Italy which employs eight staff and is funded in part by the Piedmonte Region government.

Horizon is providing a road-map to drug developers, regulatory bodies, clinicians and healthcare providers to break the cycle of ‘irrational’ cancer drug development. This is being achieved by developing and marketing key in-vitro discovery and diagnostic tools that will enable both the faster development of improved ‘targeted’ anti-cancer drugs like Herceptin, Vectibix and Erbitux and the validation and standardization of companion diagnostic tools to ensure that the correct treatments are administered to patients based upon the unique genetic-signature of their cancer.

Horizon has moved quickly into the global market via performing direct business development activities around its world-leading human gene-targeting platform technology called GENESIS™ and its derived portfolio of 150+ genetically defined X-MAN™ human cancer models. The company has announced 40+ commercial deals over the past two-years with world-leading pharmaceutical companies such as AstraZeneca, Genentech, GSK, Novartis, OSI Pharma, SuperGen and Millennium.

“Dr Darrin M Disley, Chairman of Horizon says “we are delighted to establish our new HQ facility at IQ Cambridge. Horizon is hiring right now to meet current demand for our products and services and to support our expansion into the companion diagnostics and bio-production markets. We are actively recruiting research scientists who want to work for a company of substance that does not sell-out to foreign competitors at the first opportunity to turn a quick buck for their investors. We have world-class science; people and the best Pharma partners in the industry and anyone who joins the team will be challenged, be respected and be given the opportunity of embarking on the adventure of a life-time.”